PMA TOTAL AVERAGE REVIEW TIME TO DROP MORE THAN 33% TO ABOUT 16 MONTHS IN FY 1997, FDA DEVICE CENTER REPORT SAYS; 510(k) REVIEW TIME CUT TO 98 DAYS
This article was originally published in The Gray Sheet
Executive Summary
Average total PMA review time is expected to drop to "16 months or less" in fiscal year 1997 (ending Sept. 30), FDA's Center for Devices and Radiological Health Director says in a Sept. 8 report on device center performance.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.